What Perdofen treats: main uses and benefits

The therapeutic profile of Perdofen, which contains Ibuprofen, is used across several domains for symptomatic support. The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns.

Perdofen is applied across therapeutic domains involving symptoms related to physical discomfort, systemic imbalance, and inflammatory or irritative states. It is relevant for managing symptom clusters associated with common conditions such as headache, dental pain, backache, muscle aches, minor soft-tissue injuries, and menstrual cramps (primary dysmenorrhea). Furthermore, it is commonly used to help with the general malaise and fever that often cluster with febrile states associated with the common cold or influenza.

“This medication is primarily relevant when supportive symptom management is appropriate, assisting with maintaining functional stability during symptomatic episodes.”

In situations where symptoms create noticeable physiological strain, Perdofen may support general well-being and assist patients with maintaining functional stability during symptomatic episodes.

---

Quick Fact: Relief for Acute Discomfort

Symptom Domain	Target Intensity	Typical Contexts
Pain (Analgesia)	Mild to moderate	Episodic headaches, dental work, minor injury.
Fever (Antipyresis)	Elevated temperature	Seasonal illness, febrile states.
Inflammation	Localized swelling	Soft tissue strain, menstrual discomfort.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and adolescents ge 12 years of age (typically ge 40 kg body weight).
• Children ge 6 years of age (typically ge 20 kg body weight) for appropriate formulations.

Populations for whom use is contraindicated:

• Patients with hypersensitivity to Ibuprofen or prior allergic reactions (e.g., asthma, urticaria) to aspirin or other NSAIDs.
• Individuals with active or recurrent peptic ulcer/haemorrhage or a history of GI bleeding related to previous NSAIDs.
• Patients with severe renal insufficiency, severe hepatic insufficiency, or severe uncontrolled heart failure (NYHA Class IV).
• Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
• Third trimester of pregnancy (starting at 30 weeks gestation).

Age- and Condition-Specific Eligibility Rules:

• Pregnancy (Mid-term): Use is avoided at 20 weeks or later unless specifically directed by a healthcare professional; if necessary, use the lowest effective dose for the shortest duration.
• Older Adults (Geriatric): Permitted, but requires the lowest effective dose for the shortest time due to increased risk of gastrointestinal and organ issues.
• Impaired Fertility: Use is not recommended in women attempting to conceive, as the medicine may impair female fertility.
• Cardiovascular Caution: High doses (ge 2,400 mg per day) are generally avoided in patients with established cardiovascular disease, including high blood pressure or ischaemic heart disease.

Connection to the Official Eligibility Profile

The regulatory documents establish strict criteria for Perdofen's use, defining who is allowed to take the medicine based on age and organ integrity, and listing specific patient groups for whom the medicine is absolutely contraindicated. These eligibility classifications are based on official NSAID warnings related to gastrointestinal, cardiovascular, and renal risks, ensuring that use is aligned with established safety parameters.

Interactions with other medicines and products

The interaction profile of Perdofen, which contains Ibuprofen, is formally documented in government regulatory sources, establishing constraints on co-administration with specific medicinal products and substances.

Documented Interaction Classifications

Classification	Interacting Agents / Classes
Contraindicated Combinations	Other NSAIDs (prescription or non-prescription); High-dose Acetylsalicylic Acid; Peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pharmacodynamic Risk	Anticoagulants (e.g., Warfarin); Anti-platelet agents; SSRIs; Oral Corticosteroids; Alcohol (daily consumption of three or more drinks).
Pharmacokinetic/Exposure Alteration	Lithium; Methotrexate; Cardiac Glycosides; Immunosuppressants (e.g., Ciclosporin).

Official Interaction Statements

• Co-administration with Anticoagulants is documented to increase the risk of severe bleeding and hemorrhage due to interference with platelet aggregation.
• Ibuprofen may reduce the anti-hypertensive or diuretic effect of medications such as ACE-inhibitors and Diuretics, and may cause fluid retention.
• Official labeling states that Ibuprofen reduces the renal clearance of substances like Lithium and Methotrexate, which can lead to increased plasma levels and potential toxicity.
• A timing separation rule is specified for low-dose immediate-release Aspirin: Ibuprofen should be taken at least 8 hours before or 30 minutes after the Aspirin dose to prevent interference with its anti-platelet effect.
• Interaction severity is formally noted to be increased in elderly patients, particularly regarding adverse gastrointestinal and renal outcomes when co-medicated.

The regulatory profile defines the constraints for Perdofen use by classifying combinations based on the documented risks of pharmacodynamic reinforcement (additive GI toxicity) and pharmacokinetic alterations (reduced clearance), which necessitates specific prohibitions and administration requirements.

Perdofen acts as a selective modulator of the farnesyl pyrophosphate synthase (FPPS) enzyme within the mevalonate pathway, a critical metabolic route. Its primary function involves binding to the active site of FPPS, thereby inhibiting the synthesis of farnesyl pyrophosphate (FPP) and subsequently geranylgeranyl pyrophosphate (GGPP). This action directly disrupts the post-translational modification, or prenylation, of small GTPases.

The inhibition of FPP and GGPP synthesis leads to a reduction in the prenylation of Rho, Rac, and Rab GTPase proteins within cells, particularly osteoclasts. These unprenylated GTPases cannot correctly traffic to the cellular membrane or participate in downstream signaling cascades necessary for osteoclast function. This intracellular disruption consequently impairs the formation of the osteoclast ruffled border, which is essential for secretion processes involved in bone matrix degradation.

This mechanistic cascade, originating from FPPS inhibition, culminates in a physiological decrease in bone turnover due to the suppressed activity and subsequent apoptosis (programmed cell death) of the bone-resorbing osteoclast cells. The resulting net shift favors osteoblast activity over osteoclast activity, stabilizing the skeletal matrix.

Perdofen is an oral medication, typically supplied as a tablet or capsule, and is administered based on specific guidelines that govern both non-prescription and prescription use. The fundamental principle for its administration is the use of the lowest effective dose for the shortest duration necessary to achieve a therapeutic effect.

The standard adult single dose for over-the-counter administration generally ranges from 200 mg to 400 mg, which may be repeated every 4 to 6 hours as needed. The daily dosage must not exceed 1200 mg without medical supervision. When used under medical guidance for conditions requiring higher anti-inflammatory action, single doses may increase up to 800 mg, though the total daily intake must not exceed the prescribed maximum of 3200 mg.

Official instructions recommend that the dose should be swallowed whole with a glass of water and is preferably taken with food or milk to help mitigate potential gastrointestinal discomfort. For its duration of use, non-prescription treatment is generally limited; users should not continue administration for more than 3 days for fever or 10 days for pain relief.

Population-specific constraints advise that both older adults and individuals with hepatic or renal impairment adhere strictly to the lowest possible dosage for the shortest possible duration. If a dose is missed, it is important to never double the dose to compensate.

Research evidence / Overview of Studies for Perdofen

---

Evidence for Use in Acute Pain and Discomfort

The research base for Perdofen (Ibuprofen) was studied in research contexts involving physical discomfort using Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. These studies explored fluctuating or unstable symptoms, such as acute headaches, dental discomfort, and muscle aches. Studies examined conditions related to physical discomfort by monitoring symptom intensity using standardized patient-reported scales and the time interval recorded for symptom monitoring.

Findings describe patterns observed in the studies, which documented data showing symptom change across the observed populations. However, follow-up durations were limited, typically lasting only hours or days, consistent with short-term, non-prescription use. Consequently, long-term effects are not fully established, and data for symptomatic patterns persisting beyond the acute trials remain insufficient.

---

Evidence for Use in Systemic Functional Imbalance (Fever)

Perdofen was studied for numerous Comparative Trials and Systematic Reviews for conditions related to systemic or functional imbalance (elevated body temperature). Studies monitored temporary physiological imbalance in both pediatric patients and adults. Primary outcomes monitored included the degree of change in body temperature and the sustained temperature effect observed over initial hours of treatment.

Studies monitored how symptoms evolved, and findings indicate patterns related to temperature monitoring. Evidence remains limited regarding whether findings indicate patterns different from those observed for other non-prescription fever-reducing agents. The research base is detailed for acute, short-term use, but data are still emerging for certain population subgroups and long-term consequences of frequent use.

---

What is Still Uncertain about Perdofen

Research provides context but not individual predictions, and evidence highlights what is known — and what is still uncertain. The main limitations in the existing research include modest sample sizes in certain specific subgroups and there is limited information for long-term outcomes across all non-prescription indications. Evidence quality varies across studies for specific conditions, and comparative evidence regarding other options is sometimes lacking.

Key Studies & References NICE Guideline on assessment and management of acute pain

Common questions about Perdofen (FAQ)

Q: Can Perdofen be used for a common cold or flu symptoms?

A: Official product information indicates that the active ingredient in Perdofen is indicated for the temporary relief of aches and fever that are associated with the common cold or flu. Its mechanism is designed to provide relief from both pain (analgesia) and elevated body temperature (antipyresis).

Q: Does Perdofen only work for certain types of pain?

A: Official labeling describes the indications for Perdofen’s active ingredient, confirming its use for the temporary relief of minor aches and pains from a variety of sources. These commonly include pain due to headache, toothache, muscle aches, and menstrual cramps.

Q: How long do the effects of Perdofen usually last?

A: The duration of the effect is reflected in the typical re-dosing interval found in the official instructions for administration. These instructions generally suggest that a dose can be repeated approximately every 4 to 6 hours.

Q: Is it normal to feel a bit drowsy after taking Perdofen?

A: Regulatory documents indicate that drowsiness has been reported as a potential side effect. Although it is noted as a possibility in the official product information, it is not consistently listed among the most common adverse reactions.

Q: Will Perdofen affect my ability to drive or operate machinery?

A: Official safety information advises caution when performing tasks that require full mental alertness, such as driving or operating machinery. This precaution is noted because certain side effects, including headache or dizziness, may occur.

Q: Is it possible to become dependent on Perdofen?

A: Perdofen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not scheduled under the Controlled Substances Act (CSA). Regulatory documents confirm that it does not carry the risk of physical addiction that is associated with controlled pain medicines like opioids.

Q: Can older adults (seniors) use Perdofen safely?

A: Regulatory documents state that use is permitted for older adults, but use is subject to specific precautions. Official texts emphasize the necessity of using the lowest effective dose for the shortest possible duration, due to an increased risk of serious adverse events involving the gastrointestinal system and kidneys.

Q: Is it safe to take Perdofen if I have a history of kidney problems?

A: Official warnings state that the drug is contraindicated (must not be used) in cases of severe renal (kidney) insufficiency. Official information stresses that any patient with a history of kidney problems or any level of impairment should discuss the use of this medicine with a healthcare professional before considering it.

Q: Why do some people need a prescription for Perdofen while others don't?

A: Regulatory documents define two paths for distribution based on the strength and intended use. The medicine is available over-the-counter (OTC) at lower maximum daily doses for temporary relief. Higher strengths are reserved for prescription use to manage specific conditions that require higher anti-inflammatory action under professional medical supervision.

Q: What research evidence supports the use of Perdofen for chronic pain?

A: Regulatory documents state that the majority of clinical evidence focuses on the drug's effectiveness for acute, short-term use. Clinical data covering symptomatic patterns that persist long-term, which would relate to chronic pain management, are often noted as being insufficient or limited.

Q: Does Perdofen contain any common allergens like gluten or lactose?

A: Regulatory product information includes a complete list of all inactive ingredients, or excipients. However, official documents do not typically contain specific allergen guarantees (e.g., whether starch is gluten-free), so checking the full ingredient list or contacting the manufacturer may be necessary for specific dietary concerns.

Q: What is the difference between different strengths of Perdofen?

A: Different product strengths are formulated to align with the necessary total daily dosage limits for different uses. Lower strengths are intended for non-prescription temporary relief, while higher strengths are used only under medical supervision to manage specific inflammatory conditions.

Q: Can I take Perdofen if I am breastfeeding?

A: Official information regarding use during lactation states that the transfer of the active ingredient into breast milk is minimal based on available data. It is generally regarded as compatible with breastfeeding when used at recommended doses.

Q: Can Perdofen be taken on an empty stomach?

A: Regulatory advice generally recommends taking the medicine with food or milk to help reduce the risk of gastrointestinal discomfort. Although not always strictly prohibited, taking it on an empty stomach is associated with an increased chance of stomach irritation.

Q: Will Perdofen interfere with the effects of an antidepressant?

A: Official drug interaction profiles document that the active ingredient can interact with certain types of antidepressants known as SSRIs (Selective Serotonin Reuptake Inhibitors). This co-administration is noted to potentially increase the risk of internal bleeding or hemorrhage.

Q: Is Perdofen a narcotic or opioid?

A: No. Perdofen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its mechanism of action is anti-inflammatory and it is not classified by regulatory bodies as a narcotic or opioid.

Q: Why do official documents warn against using Perdofen before surgery?

A: The warning against use, particularly before or after Coronary Artery Bypass Graft (CABG) surgery, is based on documented risks. The prohibition is necessary due to the drug’s potential to affect platelet aggregation (the ability of blood to clot), which can lead to increased bleeding, as well as the risk of serious cardiovascular events.

Q: Can people with asthma safely use Perdofen?

A: The drug is formally contraindicated (must not be used) in any patient who has previously experienced an allergic-type reaction, such as asthma or hives, after taking aspirin or other NSAIDs. Official documents note that caution should be used even in patients with pre-existing asthma.

Q: Are there specific symptoms that signal a rare but serious side effect from Perdofen?

A: Yes, official patient safety information highlights symptoms that may signal serious events. These include chest pain, sudden weakness, bloody or tarry stools, coughing up blood, unexpected swelling, or severe blistering of the skin. These symptoms are considered medical emergencies, and immediate medical care is necessary.

Q: Is it true that taking Perdofen regularly can lead to rebound headaches?

A: Regulatory and medical information for the drug class (NSAIDs) notes that frequent, regular, or prolonged use specifically for headache relief can potentially lead to Medication Overuse Headaches (MOH) or 'rebound headaches.' This observation underscores the importance of adhering to short-term use limits noted in product information.

Q: What does 'contraindication' mean in relation to Perdofen use?

A: A contraindication is a strict regulatory term that means the drug must not be used by a patient under specific conditions. This is because the known risks associated with use are determined to outweigh any potential benefit, such as in cases of severe heart failure or during the third trimester of pregnancy.

How to Store and Dispose of Perdofen: Official Requirements

Official regulatory documents define strict rules for storing, handling, and disposing of Perdofen to ensure product stability and safety. These requirements govern the practical conditions for managing the medicine.

Storage Component	Official Requirement
Temperature	Store at room temperature, generally not exceeding 25 C or 30 C. Do not freeze.
Protection	Keep the product in the original container or carton to protect it from light and moisture.
Child Safety	Must be kept out of the sight and reach of children.
Stability	Observe the stated in-use stability period after first opening or preparation; discard any unused portions after this time.
Disposal	Do not dispose of unused or expired medicine in household trash or down the drain. Return the product to a pharmacy or an official medicine take-back program in accordance with local environmental regulations.